Statins for the primary prevention of cardiovascular diseaseFiona Taylor, Hawkins Gay|Cochrane Database of Systematic Reviews|2013Cited by 1.8k
Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trialKevin J. Harrington, J. Guigay, Robert L. Ferris et al.|The Lancet Oncology|2017Cited by 431
Statins for the primary prevention of cardiovascular diseaseFiona Taylor, Shah Ebrahim|Cochrane Database of Systematic Reviews|2011Cited by 305
Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trialDavid Cella, Robert J. Motzer, Elmer Berghorn et al.|The Lancet Oncology|2016Cited by 219
Quality of life (QoL) and overall survival (OS) in patients (pts) with advanced clear-cell renal cell carcinoma (aRCC) treated with nivolumab (NIVI) vs. everolimus (EVE) in the phase III CheckMate 025 study.David Cella, Robert J. Motzer, Viktor Gruenwald et al.|Journal of Clinical Oncology|2016Cited by 4